AbbVie's Management Discusses Q1 2013 Results - Earnings Call Transcript Seeking Alpha This includes Daclizumab, which is in Phase III development in partnership with Biogen, for relapsing remitting multiple sclerosis. Data from the first of two registrational trials, the select study, were recently published in the Lancet. And results ... |
